“Adding another supplier to our proprietary development set-up will help to prevent any bottlenecks in clinical trial supply in the years ahead,” said Dr. Marlies Sproll, chief scientific officer of MorphoSys AG. “Also, establishing a commercial manufacturing process with Boehringer Ingelheim early in the development of MOR208 will clearly increase the value of this program.”
Simon Sturge, corporate senior vice president of the biopharmaceuticals division at Boehringer Ingelheim, said, “We believe that the combination of MorphoSys’s successful track record in the discovery and clinical development of antibody-based therapeutics and our proven competence in technical development and manufacturing will be an optimal fit. We look forward to supporting the team at MorphoSys with robust manufacturing processes for clinic and market supply.”